EGFR and non-small cell lung carcinoma: In the NEJ009 study, the combination of chemotherapy and first-generation EGFR-TKI achieved a better ORR (84%) compared with EGFR-TKI monotherapy (67%) in advanced NSCLC with EGFR mutations, as well as a significant improvement in PFS.11 Although there was no significant difference in OS between the 2 groups, the combination of chemotherapy and first-generation EGFR-TKI demonstrated better short-term efficacy compared to EGFR-TKI monotherapy.